Hints and tips:
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...“We need to see the promise of Crispr — that you can develop a superior product to gene therapy, precisely — holds up,” he said....
...Targeting PBMs while going easy on drugmakers is not the answer. Last year, the two largest PBMs, CVS Caremark and Express Scripts, generated $10bn of combined operating income....
...to PBMs....
...It could also hurt the bargaining power of some drugmakers that offer hefty rebates to ensure they are reimbursed for their products....
...By buying the PBM, Cigna hopes to gain more scale so it can drive a harder bargain when buying drugs and services, not just from pharmaceutical companies, but also the doctors and hospitals that provide...
...Google closed its price comparison site for financial products including auto insurance in 2016, for example....
...Just about everyone in the US agrees medicines are too expensive, but the industry is torn on who is responsible, whether it be pharmaceutical companies, wholesalers, or pharmacy benefit managers (PBMs)...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...But every drugmaker in the world has to enter price negotiations with American PBMs if they want to sell their products in the largest and most profitable healthcare market....
...In contrast to the rare diseases business, the neuroscience division had grown through the development of new products, or finding new indications for existing products, Mr Ornskov said....
...He reminded his listeners that the pharmaceuticals industry was unique in having obsolescence built into its products....
...Following a series of ever-larger acquisitions that culminated in last year’s $11bn purchase of Salix Pharmaceuticals, the company has been hit by selling over concerns about its dependence for sales growth...
...Mr Sorensen said future price increases in the US would be “very limited” and this would make Novo Nordisk dependent on shifting its product mix towards higher-value products to sustain growth....
...Together, the three pharmacy benefits managers, or PBMs, serve 215m US patients, meaning Philidor could not have continued to operate without their support....
...Valeant, the Canadian pharmaceutical company, is nearing a deal to acquire gastrointestinal drug specialist Salix, valuing that company at more than $9.7bn, according to people familiar with the matter....
...Valeant, the serial pharmaceuticals dealmaker, has agreed to buy Salix in an all-cash transaction that values the gastrointestinal specialist at $14.5bn including debt....
...The deal comes less than two months after the Dublin-based group dropped out of its $10bn pursuit of Salix following a bidding war with Valeant....
...Drugmaker Pfizer acquired medical diagnostics company Hospira for $16.8bn, deal hungry Valeant snapped up Salix Pharmaceuticals for $15.8bn, and, on Monday, pharmacy benefits manager UnitedHealth bought...
...There is a new pharmaceuticals giant in town....
...Shares of Salix Pharmaceuticals advanced 2 per cent to $172.75, on news that Valeant Pharmaceuticals had sweetened its bid for Salix and nudged Endo International out of the race....
...Salix Pharmaceuticals, a drug company focused on gastrointestinal treatments, announced on Thursday that there was excessive inventory of its products in the supply chain, so that future sales will be depressed...
...Centerview’s other high-profile pharmaceuticals deals in the last two years include Salix’s $14.5bn sale to Valeant; Intermune’s $8.3bn sale to Roche; Idenix’s $3.85bn sale to Merck & Co last year; and Onyx...
International Edition